M1 Kliniken AG has reported a strong EBIT growth of 11% and an EPS of EUR 0.86, marking a successful third quarter in 2025, alongside the strategic divestiture of its subsidiary to enhance focus on medical aesthetics.

Target Information

M1 Kliniken AG (ISIN: DE000A0STSQ8) is a leading fully integrated provider of medical aesthetic services operating across Europe and Australia. The company prides itself on high standards of treatment, which are exclusively conducted by qualified physicians. M1 Kliniken AG has established a scalable business model, operating 58 clinics in ten countries under the M1 Med Beauty brand. Their goal is to solidify their position as the world's leading vertically integrated provider of medical aesthetics.

In the third quarter of 2025, M1 Kliniken AG reported significant growth, achieving an earnings per share of EUR 0.86. This growth is attributed to their strategic focus on efficiency measures and expansion of medical capacities. The company continues to thrive in a competitive landscape, effectively enhancing both revenue and profit margins.

Industry Overview in Germany

The medical aesthetic industry in Germany is experiencing robust growth, driven by increasing consumer demand for non-invasive procedures and the focus on aesthetic enhancement. Factors such as technological advancement in medical aesthetics and heightened